Vaishali Pharma

When is the next results date for Vaishali Pharma?

No Upcoming Board Meetings

What is the bonus history of the Vaishali Pharma?

Vaishali Pharma has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced for October 15, 2024. Previously, a 3:5 bonus was issued on October 18, 2019.

Vaishali Pharma has a notable bonus history. The most recent bonus issue was announced as a 1:1 bonus, with an ex-date of October 15, 2024. Prior to that, the company issued a bonus in a 3:5 ratio, with the record date on October 18, 2019, and an ex-date of October 17, 2019. This indicates that Vaishali Pharma has actively engaged in rewarding its shareholders through bonus shares in the past.

Has Vaishali Pharma declared dividend?

No Dividend History Available

Is Vaishali Pharma overvalued or undervalued?

As of February 7, 2025, Vaishali Pharma is considered overvalued and risky, with a high PE ratio of 137.42, a PEG ratio of 9.89, and an EV to EBITDA ratio of 149.40, indicating unfavorable valuation metrics compared to its peers and a stock return of -7.57% versus the Sensex's 7.87%.

As of 7 February 2025, Vaishali Pharma's valuation grade has moved from very expensive to risky, indicating a shift in perception regarding its market position. The company is currently overvalued, as evidenced by its high PE ratio of 137.42 and a PEG ratio of 9.89, which suggests that the stock price is not justified by its earnings growth potential. Additionally, the EV to EBITDA ratio stands at 149.40, highlighting significant concerns about profitability relative to enterprise value.<BR><BR>In comparison to its peers, Vaishali Pharma's valuation metrics appear unfavorable; for instance, its PE ratio is significantly higher than the industry average, suggesting that investors are paying a premium for its shares. Notably, the company has underperformed relative to the Sensex over the past year, with a stock return of -7.57% compared to the Sensex's 7.87%. Given these factors, Vaishali Pharma is positioned as overvalued in the current market landscape.

What is the technical trend for Vaishali Pharma?

As of June 4, 2025, Vaishali Pharma's technical trend is mildly bearish, supported by moving averages and Bollinger Bands, despite a mildly bullish weekly MACD.

As of 4 June 2025, the technical trend for Vaishali Pharma has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands and moving averages on the weekly and daily time frames are all signaling mildly bearish conditions. The KST is mildly bullish weekly but also mildly bearish monthly, and the Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the moving averages and Bollinger Bands.

Who are the peers of the Vaishali Pharma?

Vaishali Pharma's peers include Mangalam Drugs, Zenith Drugs, Denis Chem Lab, Amwill Health, and others. In terms of management risk, Vaishali Pharma has below average risk, with a 1-year return of -17.84%, better than Mangalam Drugs but worse than Amwill Health.

Peers: The peers of Vaishali Pharma are Mangalam Drugs, Zenith Drugs, Denis Chem Lab, Amwill Health, Welcure Drugs, Parnax Lab, Smruthi Organic, Rajnish Wellness, Lactose (India), and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health and Smruthi Organic, while Good management risk is found at Zenith Drugs and Samrat Pharma. Average management risk is present at Mangalam Drugs, Denis Chem Lab, and Rajnish Wellness, while Below Average management risk is noted at Vaishali Pharma, Welcure Drugs, Parnax Lab, Lactose (India). Growth is Excellent at Rajnish Wellness, Good at Amwill Health and Parnax Lab, while Average growth is seen at Welcure Drugs, and Below Average growth is noted at Mangalam Drugs, Vaishali Pharma, Zenith Drugs, Denis Chem Lab, Smruthi Organic, and Lactose (India). Capital Structure is Excellent at Denis Chem Lab, Amwill Health, and Parnax Lab, Average at Zenith Drugs, while Below Average is observed at Mangalam Drugs, Vaishali Pharma, Welcure Drugs, Rajnish Wellness, Smruthi Organic, and Lactose (India).<BR><BR>Return Snapshot: The peer with the highest 1-year return is Amwill Health at 0.00%, while the peer with the lowest is Mangalam Drugs at -18.81%. Vaishali Pharma's 1-year return is -17.84%, which is better than Mangalam Drugs but worse than Amwill Health. Additionally, the six-month return is negative for Mangalam Drugs, Vaishali Pharma, Zenith Drugs, and Lactose (India).

Who are in the management team of Vaishali Pharma?

As of March 2022, the management team of Vaishali Pharma includes Atul Vasani (Chairman & Managing Director), Jagruti Vasani (Whole-time Director), Dewansh Vasani (Executive Director), and four independent directors: Ashvin Jamnadas Ganatra, Manish Bhagwandas Ved, Pratik Vikram Jakhelia, along with Vishwa Mekhia as Company Secretary & Compliance Officer.

As of March 2022, the management team of Vaishali Pharma includes the following individuals:<BR><BR>1. Atul Vasani - Chairman & Managing Director<BR>2. Jagruti Vasani - Whole-time Director<BR>3. Dewansh Vasani - Executive Director<BR>4. Ashvin Jamnadas Ganatra - Independent Director<BR>5. Manish Bhagwandas Ved - Independent Director<BR>6. Vishwa Mekhia - Company Secretary & Compliance Officer<BR>7. Pratik Vikram Jakhelia - Independent Director<BR><BR>As of March 2022, the management team consists of a mix of executive and independent directors, along with a compliance officer, reflecting a structured leadership approach within the company.

What does Vaishali Pharma do?

Vaishali Pharma Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, was incorporated in 2008 and reported net sales of 322 Cr and a net loss of 43 Cr for the quarter ending March 2025. The company has a market cap of INR 134 Cr and key financial metrics include a P/E of 138.00 and a debt-equity ratio of 0.18.

Overview:<BR>Vaishali Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Vaishali Pharma Ltd was incorporated in 2008 as a Private Limited Company. It acquired the business of M/s. Vaishali Pharmachem from its promoter Mr. Atul Vasani on July 1, 2008. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 322 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -43 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 134 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 138.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.18 <BR>Return on Equity: 1.21% <BR>Price to Book: 1.98 <BR><BR>Contact Details:<BR>Address: 706 to 709 7th Floor Aravali, Business Centre Borivali(W) Mumbai Maharashtra : 400092 <BR>Tel: 91-22-28928833 <BR>Email: investor@vaishalipharma.com <BR>Website: http://www.vaishalipharma.com

Who are the top shareholders of the Vaishali Pharma?

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani with 21.1%, and Sapan Anil Shah as the highest public shareholder at 6.82%. Individual investors own 65.24% of the company, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani, who holds the largest stake at 21.1%. The highest public shareholder is Sapan Anil Shah, with a holding of 6.82%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

How big is Vaishali Pharma?

As of 24th July, Vaishali Pharma Ltd has a market capitalization of 135.00 Cr, with recent net sales of 99.03 Cr and a net profit of 0.82 Cr. The balance sheet for March 2024 shows shareholder's funds of 42.84 Cr and total assets of 79.78 Cr.

As of 24th July, Vaishali Pharma Ltd has a market capitalization of 135.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vaishali Pharma reported Net Sales of 99.03 Cr and a Net Profit of 0.82 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 42.84 Cr and Total Assets of 79.78 Cr.

How has been the historical performance of Vaishali Pharma?

Vaishali Pharma has experienced fluctuating financial performance, with net sales increasing from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, but significant declines in profitability and negative cash flow in March 2025. Despite growth in total assets and a reduction in debt, the company's operating profit margin and profits before and after tax have sharply decreased.

Answer:<BR>The historical performance of Vaishali Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Vaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was as high as 13.09% in March 2023, fell sharply to 0.1% in March 2025. Profit before tax also declined significantly from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025, while profit after tax decreased from INR 6.60 crore to INR 0.82 crore in the same period. The company's total assets increased from INR 66.08 crore in March 2020 to INR 109.66 crore in March 2025, reflecting growth in shareholder's funds, which rose to INR 64.92 crore. Despite this growth, total debt decreased from INR 14.72 crore in March 2020 to INR 8.50 crore in March 2025. Cash flow from operating activities has been negative in March 2025 at INR -18.00 crore, contrasting with positive cash flows in previous years. Overall, Vaishali Pharma's financial performance indicates a complex trajectory with growth in sales and assets but challenges in profitability and cash flow management.

Should I buy, sell or hold Vaishali Pharma Ltd?

Which are the latest news on Vaishali Pharma?

Why is Vaishali Pharma Ltd falling/rising?

As of 17-Mar, Vaishali Pharma Ltd's stock price is rising by 1.34%, despite a significant decline in value over the past year and three years. The stock remains under pressure, trading close to its 52-week low, with weak long-term fundamentals, although increased promoter confidence may attract some investor interest.

As of 17-Mar, Vaishali Pharma Ltd's stock price is currently rising, as indicated by a change of 0.08, or 1.34%, from the previous close. This uptick in price comes despite the company's overall poor performance metrics, including a significant decline in stock value over various periods, such as a 51.59% drop over the past year and a staggering 60.17% decrease over the last three years. <BR><BR>The stock is trading close to its 52-week low, just 3.13% above the low of Rs 5.88, which suggests that while there is a slight upward movement today, the stock remains under pressure. Additionally, the company has shown weak long-term fundamental strength, with a -202.97% CAGR growth in operating profits over the last five years and a negative EBITDA, indicating financial instability.<BR><BR>However, a positive factor contributing to the current rise in stock price is the increased confidence from promoters, who have raised their stake in the company by 5.29% in the last quarter, now holding 31.61% of the company. This increase in ownership can be interpreted as a sign of confidence in the company's future prospects, potentially attracting some investor interest.<BR><BR>Despite today's performance, the stock's overall trajectory remains concerning, as it has consistently underperformed against benchmarks and has seen a decline in investor participation, with delivery volume falling by 15.67% against the five-day average. Therefore, while the stock is experiencing a brief rise, the long-term outlook remains negative due to fundamental weaknesses and ongoing underperformance.

Why is Vaishali Pharma Ltd falling/rising?

As of 18-Mar, Vaishali Pharma Ltd's stock price is slightly rising at Rs. 6.13, but it has a long-term decline of -50.04% over the past year and is trading below moving averages, indicating a bearish trend. Despite a minor uptick today, the stock faces ongoing challenges, including reduced investor interest and weak financial fundamentals.

As of 18-Mar, Vaishali Pharma Ltd's stock price is experiencing a slight rise, currently at Rs. 6.13, which reflects an increase of 0.06 or 0.99%. However, this rise occurs against a backdrop of significant long-term declines in the stock's performance. Over the past year, the stock has generated a return of -50.04%, and it has consistently underperformed against the benchmark, the Sensex, in each of the last three annual periods.<BR><BR>Despite today's positive movement, the stock is trading below its moving averages across various time frames, indicating a bearish trend. Additionally, the stock hit a new 52-week low of Rs. 5.67 earlier today, highlighting ongoing challenges. Investor participation is also declining, with delivery volume falling by 29.11% compared to the five-day average, suggesting reduced interest from traders.<BR><BR>On a more positive note, there has been an increase in promoter confidence, with promoters raising their stake in the company by 5.29% over the previous quarter. This could indicate a belief in the company's future potential, but it contrasts sharply with the company's weak long-term fundamentals, including a -202.97% CAGR growth in operating profits over the last five years and a negative EBITDA.<BR><BR>In summary, while there is a minor uptick in the stock price today, the overall trend remains negative due to significant long-term underperformance, declining investor participation, and weak financial fundamentals.

Why is Vaishali Pharma Ltd falling/rising?

As of 19-Mar, Vaishali Pharma Ltd's stock price is at 5.98, down 2.45%, reflecting significant underperformance with a year-to-date decline of 30.63% and a 52.43% drop over the past year. The company's weak financial health, declining investor interest, and poor operating profit growth contribute to its falling stock price.

As of 19-Mar, Vaishali Pharma Ltd's stock price is falling, currently at 5.98, reflecting a decrease of 0.15 or 2.45%. The stock has underperformed significantly over various time frames, with a one-week decline of 5.53% and a one-month drop of 23.14%. Year-to-date, the stock has decreased by 30.63%, and over the past year, it has plummeted by 52.43%. This consistent underperformance is evident as the stock has lagged behind the benchmark Sensex, which has shown a slight increase of 0.41% over the same period.<BR><BR>Today's performance indicates that the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a decline in investor participation, with delivery volume falling by 6.01% compared to the 5-day average. This suggests a lack of confidence among investors.<BR><BR>Despite a recent increase in promoter confidence, with a 5.29% rise in their stake, the overall financial health of the company remains concerning. The company has reported a staggering -202.97% CAGR growth in operating profits over the last five years, indicating weak long-term fundamental strength. Furthermore, the company's ability to service its debt is weak, with a poor EBIT to Interest ratio of 1.56, and it has generated a low return on equity of 8.79%. The latest financial results show a significant decline in net sales and profits, with a negative EBITDA over the past year.<BR><BR>In summary, the combination of poor financial performance, declining investor interest, and consistent underperformance against benchmarks has led to the falling stock price of Vaishali Pharma Ltd.

Why is Vaishali Pharma Ltd falling/rising?

As of 20-Mar, Vaishali Pharma Ltd's stock price is at 5.98, unchanged from the previous session, and has seen a significant decline of 30.63% year-to-date and 51.34% over the past year. The company's weak financial fundamentals, poor profitability, and declining investor interest indicate a continued downward trend.

As of 20-Mar, Vaishali Pharma Ltd's stock price is currently at 5.98, showing no change from the previous trading session. The stock has been experiencing a significant decline over various time periods, with a year-to-date drop of 30.63% and a staggering 51.34% decrease over the past year. This consistent underperformance is highlighted by the fact that the stock has underperformed against the benchmark, the Sensex, in each of the last three annual periods.<BR><BR>Several factors contribute to the stock's decline. The company has reported weak long-term fundamental strength, evidenced by a -202.97% compound annual growth rate (CAGR) in operating profits over the last five years. Additionally, the company's ability to service its debt is concerning, with a poor EBIT to Interest ratio of 1.56. The return on equity has averaged only 8.79%, indicating low profitability relative to shareholders' funds.<BR><BR>Recent financial results have also been disappointing, with a net profit after tax (PAT) of Rs 3.76 crore reflecting a decline of 26.42% and net sales falling by 11.68% in the last quarter. Furthermore, the stock is trading at a risky valuation compared to its historical averages, with profits plummeting by 96% over the past year.<BR><BR>Despite some positive indicators, such as rising promoter confidence with a 5.29% increase in their stake, the overall outlook remains bleak. The stock is trading below all major moving averages and has seen a significant drop in investor participation, with delivery volume falling by 60.43% against the five-day average. This combination of weak financial performance, declining investor interest, and consistent underperformance against benchmarks suggests that Vaishali Pharma Ltd is currently in a downward trend.

Why is Vaishali Pharma Ltd falling/rising?

As of 23-Mar, Vaishali Pharma Ltd's stock price is at Rs. 5.82, reflecting a 2.68% decrease and a significant decline over the past month and year. The stock is underperforming compared to the Sensex and shows bearish trends, with declining investor participation contributing to its falling price.

As of 23-Mar, Vaishali Pharma Ltd's stock price is falling, currently at Rs. 5.82, which reflects a decrease of Rs. 0.16 or 2.68%. The stock has shown a significant decline over various periods, including a 24.51% drop over the past month and a staggering 52.91% decrease over the past year. Additionally, the stock hit a new 52-week low of Rs. 5.67 today, indicating ongoing downward pressure.<BR><BR>The performance of Vaishali Pharma is also underwhelming compared to the benchmark Sensex, which has only declined by 3.83% over the past week and 12.45% over the past month. Furthermore, the stock is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend.<BR><BR>Investor participation appears to be declining as well, with delivery volume dropping by 24.96% against the 5-day average. This lack of interest from investors further contributes to the stock's falling price. Overall, the combination of poor performance metrics, low investor engagement, and a breach of key support levels are the primary reasons for the decline in Vaishali Pharma Ltd's stock price.

Why is Vaishali Pharma Ltd falling/rising?

As of 24-Mar, Vaishali Pharma Ltd's stock is at Rs. 5.75, down 1.2%, with a year-to-date decline of 33.29% and a 51.60% drop over the past year. The company faces significant financial challenges, including negative growth in operating profits and declining net sales, leading to a negative outlook despite a slight increase in promoter confidence.

As of 24-Mar, Vaishali Pharma Ltd's stock price is falling, currently at Rs. 5.75, reflecting a decrease of Rs. 0.07 or 1.2%. The stock has significantly underperformed in various time frames, with a year-to-date decline of 33.29% and a staggering 51.60% drop over the past year. Additionally, the stock has recently hit a new 52-week low of Rs. 5.67, indicating ongoing weakness.<BR><BR>The company's performance metrics reveal concerning trends, including a negative compound annual growth rate (CAGR) of -202.97% in operating profits over the last five years and a poor EBIT to Interest ratio of 1.56, suggesting difficulties in servicing debt. Furthermore, the net sales for the last quarter fell by 11.68%, and the profit after tax has decreased by 26.42%. These financial struggles contribute to a perception of weak long-term fundamental strength.<BR><BR>Despite a recent increase in promoter confidence, with a 5.29% rise in their stake, the overall outlook remains negative due to the company's consistent underperformance against benchmarks like the BSE500 over the last three years. The stock's liquidity appears adequate, but the significant decline in profitability, alongside a negative EBITDA and a return on equity of only 8.79%, reinforces the bearish sentiment surrounding Vaishali Pharma Ltd.

Why is Vaishali Pharma Ltd falling/rising?

As of 25-Mar, Vaishali Pharma Ltd's stock price is at Rs. 5.73, reflecting a significant decline of -50.26% over the past year and hitting a new 52-week low. The company's weak fundamentals and consistent underperformance against benchmarks indicate a bleak outlook for the stock.

As of 25-Mar, Vaishali Pharma Ltd's stock price is falling, currently at Rs. 5.73, reflecting a change of -0.02 (-0.35%). The stock has underperformed significantly over various time frames, with a 1-week decline of -6.53%, a 1-month drop of -23.19%, and a year-to-date decrease of -33.53%. Over the past year, the stock has plummeted by -50.26%, starkly contrasting with the BSE500 benchmark, which has only seen a -1.53% decline during the same period.<BR><BR>Today's performance indicates that the stock has hit a new 52-week low of Rs. 5.6, further emphasizing its downward trajectory. It is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Additionally, while there has been a slight increase in delivery volume, this does not offset the overall negative sentiment surrounding the stock.<BR><BR>The company's fundamentals also reflect weakness, with a staggering -202.97% compound annual growth rate (CAGR) in operating profits over the last five years. The company's ability to service its debt is concerning, indicated by a poor EBIT to Interest ratio of 1.56. Furthermore, the latest financial results show a decline in net sales by -11.68% and a significant drop in profit after tax (PAT) by -26.42%. <BR><BR>Despite some positive signals, such as rising promoter confidence with a 5.29% increase in their stake, the overall outlook remains bleak due to consistent underperformance against benchmarks and a negative EBITDA trend. Thus, the combination of poor financial performance, significant declines in stock value, and weak long-term fundamentals contributes to the ongoing fall in Vaishali Pharma Ltd's stock price.